Guyer William's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jul 8, 2026
- Accession no.
- 0001193125-26-298865
- Filed
- Jul 8, 2026, 7:54 PM ET
- Trade date
- Jul 7, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.86M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Guyer WilliamCIK 0001879013 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | MOption exerciseAcquired | +20,000 | $21.65 | +$433,000 | 23,985 | Direct | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −19,048 | $93.11F3 | −$1,773,481.18 | 4,937 | Direct | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −952 | $93.54F4 | −$89,048.46 | 3,985 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 130,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $92.50 to $93.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $93.52 to $93.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.